Table 2. SGLT2 Inhibitors Prescribed to the Subjects Studied at Baseline (n = 50).
Dapagliflozin 5 mg | 16 (32%) |
Ipragliflozin 25 mg | 4 (8%) |
Ipragliflozin 50 mg | 10 (20%) |
Tofogliflozin 20 mg | 7 (14%) |
Luseogliflozin 2.5 mg | 11 (22%) |
Canagliflozin 100 mg | 1 (2%) |
Empagliflozin 10 mg | 1 (2%) |